tbuckley/cabot-search huggingface dataset:
Assessing Depression Among New Fathers—Reply
Authors: Lisa Underwood, Susan M. B. Morton, Karen E. Waldie
Journal: JAMA Psychiatry (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Psychiatry HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Psychiatry journal
Perspective of Residency Program Directors on Accreditation Council for Graduate Medical Education Changes in Resident Work Environment and Duty Hours
Authors: Michael O. Meyers, George A. Sarosi, Karen J. Brasel
Journal: JAMA Surgery (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
Has reimbursement for knee osteoarthritis treatments now reached ‘postfact’ status?
Authors: John Orchard, Maarten H Moen
Journal: British Journal of Sports Medicine (2017)

One of the words of 2016 ‘postfact’ was applied mainly to the field of politics. Many of us working in healthcare, based on science, have been concerned by the recent trend for populists to ‘choose their own facts’. But is healthcare immune to its own versions of fake news and postfact logic? And is it limited to the obvious fringe examples like the antivaccination movement?

Many treatments in medicine become popular based on ‘promising’ results from low-quality studies that are subsequently found to be ineffective based on multiple high-quality randomised control trials (RCTs) and their meta-analysis in systematic reviews (SRs).

While scientific publication evolves quite rapidly, funding in healthcare is very static. Funding for healthcare procedures historically appears to be based on popularity (widespread use) and expert guidelines rather than evidence based. And then, once funding for a medical procedure becomes ‘established’, the burden of evidence required to remove the funding appears to be very high. However, the …
Genetic Counselor Recommendations for Cancer Predisposition Evaluation and Surveillance in the Pediatric Oncology Patient
Authors: Harriet Druker, Kristin Zelley, Rose B. McGee, Sarah R. Scollon, Wendy K. Kohlmann, Katherine A. Schneider, Kami Wolfe Schneider
Journal: Clinical Cancer Research (2017)

Abstract As the understanding of the genetic etiology of childhood cancers increases, the need for the involvement of experts familiar with the provision of genetic counseling for this population is paramount. In October 2016, the American Association for Cancer Research organized the AACR Childhood Cancer Predisposition Workshop in which international experts in pediatric cancer predisposition met to establish surveillance guidelines for children with cancer predisposition. Identifying for whom, when, why, and how these cancer predisposition surveillance guidelines should be implemented is essential. Genetic counselors invited to this workshop provide a genetic counseling framework for oncology professionals in this article. Points of entry and recommendations regarding the provision and timing of the initial and subsequent genetic counseling sessions are addressed. The genetic counseling and testing processes are reviewed, and the psychologic impact related to surveillance is explored. Pediatric cancer genetics will continue to grow and evolve as a field, and genetic counseling services will be vital to ensure appropriate identification and management of at-risk children moving forward. Clin Cancer Res; 23(13); e91–e97. ©2017 AACR. See all articles in the online-only CCR Pediatric Oncology Series.
Correctable Causes of Recurrent Reflux, Dysphagia and Vomiting after Anti-Reflux Surgery
Authors: VM Patel, H Dowson, A Botha
Journal: Endoscopy (2006)

Aims: Ten percent of patients, who have had anti-reflux surgery for GORD, require revision operations for intolerable recurrent symptoms. Our purpose was to determine the surgically correctable causes of these symptoms.
Breast Regression Protein–39/Chitinase 3–Like 1 Promotes Renal Fibrosis after Kidney Injury via Activation of Myofibroblasts
Authors: Tinika A. Montgomery, Leyuan Xu, Sherene Mason, Amirtha Chinnadurai, Chun Geun Lee, Jack A. Elias, Lloyd G. Cantley
Journal: Journal of the American Society of Nephrology (2017)

The normal response to kidney injury includes a robust inflammatory infiltrate of PMNs and macrophages. We previously showed that the small secreted protein breast regression protein–39 (BRP-39), also known as chitinase 3–like 1 (CHI3L1) and encoded by the Chi3l1 gene, is expressed at high levels by macrophages during the early stages of kidney repair and promotes tubular cell survival via IL-13 receptor α 2 (IL13R α 2)–mediated signaling. Here, we investigated the role of BRP-39 in profibrotic responses after AKI. In wild-type mice, failure to resolve tubular injury after unilateral ischemia-reperfusion injury (U-IRI) led to sustained low-level Chi3l1 mRNA expression by renal cells and promoted macrophage persistence and severe interstitial fibrosis. Analysis of macrophages isolated from wild-type kidneys 14 days after U-IRI revealed high-level expression of the profibrotic BRP-39 receptor Ptgdr2 / Crth2 and expression of the profibrotic markers Lgals3 , Pdgfb , Egf , and Tgfb . In comparison, injured kidneys from mice lacking BRP-39 had significantly fewer macrophages, reduced expression of profibrotic growth factors, and decreased accumulation of extracellular matrix. BRP-39 depletion did not affect myofibroblast accumulation but did attenuate myofibroblast expression of Col1a1 , Col3a1 , and Fn1 . Together, these results identify BRP-39 as an important activator of macrophage-myofibroblast crosstalk and profibrotic signaling in the setting of maladaptive kidney repair.
Physiopathological determinants of human infertility
Authors: None The ESHRE Capri Workshop Group
Journal: Human Reproduction Update (2002)

Successful management of infertility involves the use of appropriate diagnostic tests and treatments, and knowledge of prognostic factors such as age of the female partner and duration of infertility. The assessment of infertility may reveal disorders that cause morbidity in the normally fertile population, which might or might not contribute to the infertility. Endocrine dysfunction is a significant cause of infertility due to amenorrhoea and dysfunctional uterine bleeding, and hirsutism is a familiar problem in the normal population. Some genetic abnormalities cause infertility in males and females and create implications for the progeny of infertile couples. Sexually transmitted diseases cause illness and healthcare expenditure among young adults, and can also result in tubal infertility. Congenital disorders of the uterus and fibromyomas are not rare and they are frequently asymptomatic, but in some cases uterine anomalies may contribute to infertility and pregnancy loss. Autoimmunity underlies some common diseases, especially among females, and it can also be associated with pregnancy loss. When such widely distributed factors are identified during the diagnostic assessment of subfertile couples, it is important to distinguish between a coincidental association and a specific relationship to the infertility.
An atlas of bloodstream-accessible bone marrow proteins for site-directed therapy of acute myeloid leukemia
Authors: L Angenendt, S Reuter, D Kentrup, A S Benk, F Neumann, J Hüve, A C Martens, C Schwöppe, T Kessler, L H Schmidt, T Sauer, C Brand, J-H Mikesch, G Lenz, R M Mesters, C Müller-Tidow, W Hartmann, E Wardelmann, D Neri, W E Berdel, C Roesli, C Schliemann
Journal: Leukemia (2017)
<i>NTRK1-3</i> point mutations in poor prognosis thyroid cancers.
Authors: Nicole M. Iniguez-Ariza, Keith Christopher Bible, John C. Morris, Ashish V. Chintakuntlawar, Vijayalakshmi Shridhar, Robert C. Smallridge, Michael E. Menefee, Crystal Hilger, Eric Allan Severson, Mabel M Ryder
Journal: Journal of Clinical Oncology (2017)

6087 Background: NTRK1-3 fusions, identified in pediatric radiation-associated thyroid cancers, are low frequency oncogenic drivers that can trigger constitutive activation of TrK1-3 tyrosine kinase domains with responsively heightened downstream signaling through RAS-MAPK, PI3K-AKT, and/or PLCγ-PKC. NTRK point mutations are rare and of largely uninvestigated oncogenic potential, but some appear oncogenic. Methods: Advanced thyroid cancer (TC) patients (pts) requiring systemic therapy at Mayo Clinic sites underwent tumor genetic interrogation using Foundation One analyses with the goal of informing salvage therapeutic strategies. In this IRB-approved study, data from pts with TCs bearing NTRK point mutations were retrospectively analyzed, as this occurrence was unexpected but potentially of prognostic and/or therapeutic relevance. Results: Five of 55 pts (9%) with advanced TCs subject to Foundation One tumor interrogation had NTRK1-3 point mutations (allele frequency, AF, 15-49%); none had fusions. All 5 tumors had microsatellite stability; 4/5 had low tumor mutation burden (2-5 mutations/megabase). NTRK mutations in 3 anaplastic TC (ATC) pts (15% prevalence) were: NTRK3 I749M (AF 15%; overall survival, OS, 15 mos), NTRK1 R744H (AF not available; OS 9.5 mos), and NTRK1 R583H (AF 20.1%; OS &gt; 4.9 mos); NTRK2 S167Y (AF 49%; OS &gt; 51 mos) or NTRK1 R6W (AF 42%; OS &gt; 60 mos) were found in one papillary (PTC) and one Hürthle cell (HCC) TC pt respectively (summary table below). Conclusions: NTRK point mutations, but not fusions, were unexpectedly identified in 9% of assessed advanced TCs - but remarkably in 15% of ATCs. Mutated NTRKs, along with oncogenic p53 and TERT, may contribute to TC progression, especially in ATC, consequent to downstream activation of MAPK and PI3K-AKT pathways. We posit that NTRK point mutations may have therapeutic implications for treatment of refractory disease. [Table: see text]
NGR-hTNF as second-line treatment in malignant pleural mesothelioma (MPM).
Authors: Gilda Rossoni, Vanesa Gregorc, Maria Grazia Viganò, Alessandra Bulotta, Domenico Ghio, Antonio Lambiase, Claudio Bordignon
Journal: Journal of Clinical Oncology (2012)

7076 Background: NGR-hTNF exploits the asparagine-glycine-arginine (NGR) peptide for selectively targeting tumor necrosis factor (TNF) to cancer endothelial cells. Tumor hypervascularity is an independent predictor of poor overall survival (OS) in MPM patients (pts). Methods: We report long-term results of a phase II trial that assessed NGR-hTNF in MPM pts with performance status (PS) ≤ 2 and radiologic progressive disease (PD) after a pemetrexed-based regimen. NGR-hTNF was given at 0.8 µg/m 2 every 3 weeks (q3w) in 43 pts and weekly (q1w) in 14 pts. Primary endpoint was progression free survival (PFS), with restaging done q6w by MPM-modified RECIST criteria, while secondary aims included disease control (DC) rate and OS. We also tested the impact on outcome of neutrophil to lymphocyte ratio (NLR) at baseline (median 3; interquartile range 2-5). Median follow-up was 32.5 months (95% CI 27.5-37.5). Results: Baseline characteristics were (n=57): median age 57 years; M/F 35/22; PS 0/1-2 31/26; EORTC score good/poor 45/12. Median treatment free interval on prior therapy was 4.3 months. Only one drug-related grade ≥ 3 adverse events (AEs) was noted, common grade 1/2 AEs being transient chills (75%). No higher toxicity was reported using the q1w schedule. Median PFS was 2.8 months (95% CI 2.2-3.3). DC rate was 46% (95% CI 32-59; 26/57 pts; 1 partial response, 25 stable diseases) and was maintained for a median time of 4.7 months (95% CI 4.0-5.4). OS rates at 1 and 2 years were 47% and 16%, respectively. Median OS was longer in pts with DC than in those with early PD (16.2 and 8.3 months, respectively; p=.02). According to schedule, 6-month PFS rates were 11% and 36% and 2-year OS rates were 12% and 29% for q3w and q1w, respectively. In pts with DC, median PFS were 4.4 and 9.1 months and median OS were 13.3 and 24.8 months for q3w and q1w, respectively. By Cox analyses, a PS of 0 (p=.01) and a low baseline NLR (p=.004) were the only variables associated with improved OS. Median OS in pts stratified by NLR ≤ 2, 3 to 4, and ≥ 5 were 15.7, 10.5, and 4.2 months, respectively (p=.0002 for trend). Conclusions: NGR-hTNF showed promising PFS and OS in this study. A double-blind phase III trial is currently testing best investigator choice ± NGR-hTNF q1w in pemetrexed-pretreated MPM pts (NCT01098266).
A Randomized Controlled Trial of Medication and Cognitive-Behavioral Therapy for Hypochondriasis
Authors: Brian A. Fallon, David K. Ahern, Martina Pavlicova, Iordan Slavov, Natalia Skritskya, Arthur J. Barsky
Journal: American Journal of Psychiatry (2017)

Objective: Prior studies of hypochondriasis demonstrated benefits for pharmacotherapy and for cognitive-behavioral therapy (CBT). This study examined whether joint treatment offers additional benefit. Method: Patients with DSM-IV hypochondriasis (N=195) were randomly assigned to one of four treatments—placebo, CBT, fluoxetine, or joint treatment with both fluoxetine and CBT. Evaluations assessed hypochondriasis, other psychopathology, adverse events, functional status, and quality of life. The primary analysis assessed outcome at week 24 among the intent-to-treat sample, with responders defined as having a 25% or greater improvement over baseline on both the Whiteley Index and a modified version of the Yale-Brown Obsessive Compulsive Scale for hypochondriasis (H-YBOCS-M). The Cochran-Armitage trend test assessed the hypothesized pattern of response: joint treatment > CBT or fluoxetine treatment > placebo treatment. Results: The predicted pattern of response was statistically significant, as shown by the following responder rates: joint treatment group, 47.2%; single active treatment group, 41.8%; and placebo group, 29.6%. Responder rates for each active treatment were not significantly different from the rate for placebo. Secondary analyses of the Whiteley Index as a continuous measure revealed that, compared with placebo, fluoxetine (but not CBT) was significantly more effective at week 24 in reducing hypochondriasis and had a significantly faster rate of improvement over 24 weeks. Fluoxetine also resulted in significantly less anxiety and better quality of life than placebo. Dropout rates did not differ between groups, and treatment-emergent adverse events were evenly distributed. Conclusions: This study supports the safety, tolerance, and efficacy of fluoxetine for hypochondriasis. Joint treatment provided a small incremental benefit. Because approximately 50% of patients did not respond to the study treatments, new or more intensive approaches are needed.
Analysis of miRNA – microarray data of breast cancer for the prediction of lymph node invasion
Authors: Ann Smeets, Olivier Gevaert, Bart Claes, Anneleen Daemen, Diether Lambrechts, Hans Wildiers, Isabelle Vanden Bempt, Robert Paridaens, Patrick Neven, Marie-Rose Christiaens
Journal: Annals of Oncology (2010)
Phase II randomized study of two oxaliplatin and 5-fluorouracil regimens in the second line palliative chemotherapy of metastatic pancreatic cancer patients (MazoviaGI-1)
Authors: Dawid Proszynski, Agnieszka Kolasinska-Cwikła, Malgorzata Stolarek, Alina Kepka, Agnieszka Domurad, Joanna Drapala-Wilkosz, Jacek Krynski, Anna Cencelewicz-Lesikow, Ewa Kosakowska, Jacek Zwolinski, Maciej Temnyk, Katarzyna Marcisz-Grzanka, Lucjan Wyrwicz
Journal: Annals of Oncology (2017)
Why didn’t patients use it? Engagement is the real story in Gilbody et al. (2015), not effectiveness.
Authors: M. Jones, D.D. Ebert, C. Jacobi, I. Beintner, T. Berger, D. Gorlich, M.P. Schaub, H. Riper, U. Schmidt, R. Banos, C. Botella
Journal: BMJ (2015)
Dose escalation of radiotherapy (RT) for locally advanced head and neck carcinomas treated with concomitant chemotherapy (CT) and RT: Results of the GORTEC 2004-01 randomized trial.
Authors: Jean Bourhis, Anne Auperin, Marc Alfonsi, xu Shan Sun, Michel Rives, Yoann Pointreau, Cedrik Lafond, Pierre Boisselier, Pierre Graff, Juliette Thariat, Yungan Tao
Journal: Journal of Clinical Oncology (2017)

6015 Background: Concomitant CT-RT is a well established standard of care (SoC) in locally advanced (LA) squamous cell carcinomas of the head and neck (SCCHN). While there is a well established dose effect relationship for RT alone in these cancers, it is not known whether this also applies to concomitant CT-RT. Methods: Patients were randomized between 75 Gy/7 weeks (Arm A) versus 70 Gy/35F in 7 weeks (Arm B). A sequential boost of 10 times 2.5 Gy after 50Gy/25F was given to the initial gross tumor volume (GTV) in Arm A. IMRT was used for arm A and 3D conformal RT for arm B. In both arms, patients (pts) received during RT 3 cycles of cisplatin at 100 mg/m2. Inclusion criteria were pts fit for receiving high dose cisplatin, non metastatic, non operated stage III-IV SCC of oral cavity, oro/hypopharynx. A 1:1 randomization was done by minimization on centers, N &amp; T stages &amp; GTV uni/bilateral. To detect a hazard ratio (HR) of 0.56 in locoregional (LR) control, inclusion of 310 pts was required to observe 109 LR progressions and achieve 85% power at 2-sided significance level of 0.05. Results: Between 2005 and 2015, 188 pts were randomized: 82% males, median age 58 years, 85% oropharynx. The accrual rate was slower than expected, due to the fact that IMRT became a SoC and was only allowed in arm A. As a consequence the trial was discontinued after inclusion of 188 patients. The majority of pts had stage IVa (73% vs 72%). All initial characteristics were well balanced between arms. The median follow-up was 4.7 years, not different between arms. Acute and late xerostomia were markedly improved in arm A (IMRT arm). The 1-year grade 0-1 salivary toxicity (RTOG) was 81% and 34% (p&lt; 0.0001) in arm A and B respectively. At 3 years these rates were 92% vs 53% (p=0.0003). The increase of the dose to the GTV with IMRT did not transfer in a higher LR control probability with an adjusted HR of 0.88 [95%CI 0.51-1.52] (p=0.63). PFS, overall survival were not significantly different between the 2 arms. Conclusions: The dose escalation of RT to the GTV did not improve LR control in patients treated with concomitant CT-RT. This trial adds some new evidence level 1 in favor of IMRT in LA SCCHN. Clinical trial information: NCT00158678.
Human Papillomavirus Vaccination and Keratinocyte Carcinomas
Authors: Jonathan E. Mayer
Journal: JAMA Dermatology (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Dermatology journal
Water in Biological Systems
Authors: I. D. Kuntz, A. Zipp
Journal: New England Journal of Medicine (1977)

IN this paper we marshal the facts that are available on the properties of water molecules found in cellular and subcellular materials. We begin with a consideration of the properties of water molecules as found in pure liquid water, proceed to the properties of water molecules in protein solutions and then treat water molecules in cells and tissues. Our final section discusses the application of measurements on water to questions of biomedical interest.Properties of Water Molecules in Pure Liquid Water1 EnergeticsTo remove a water molecule from the pure liquid at 25°C takes approximately 10.5 kcal per mole of . . .
Abstract #390: BNIP1 regulates autophagy through its interactinon with Bif-1
Authors: Henrick Horita, Andrew Thorburn
Journal: Cancer Research (2009)

With 1,437,180 new cancer cases and 565,650 deaths from cancers projected in the USA this year it is evident that cancer is a health crisis that desperately requires our focus if we hope to manage the disease. Cancers such as Glioblastoma Multiforme (GBM), which has a five year survival rate of less than 5% with current therapies are resistant to most apoptosis therapeutics, but may be more susceptible to autophagy stimulants such as temozolamide. Thus, gaining insight into the autophagic pathway may provide promising therapeutics to treat GBM. BNIP1, a Bcl-2 family protein, has previously been shown to play an integral role in ER network integrity. We found that BNIP1 also regulates autophagy. Overexpression of BNIP1 delays autophagy as demonstrated by altered processing of and recruitment to autophagosomes the key autophagic marker LC3II. Furthermore, depleting BNIP1 levels with shRNA decreases autophagosomal formation and prevents LC3 II processing. Co-immunoprecipitation experiments showed that BNIP1 can interact directly with Bif-1, which regulates the autophagosome nucleation complex. Since BNIP1 plays a role in ER network integrity its interaction with Bif-1 may be important for the delivery of isolation membranes necessary for phagophore formation. Thus, we conclude that BNIP1 plays a critical role in autophagosomal formation through direct interaction with proteins involved in the nucleation complex.  Citation Information: In: Proc Am Assoc Cancer Res; 2009 Apr 18-22; Denver, CO. Philadelphia (PA): AACR; 2009. Abstract nr 390.